A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Bevacizumab|DRUG: Paclitaxel
Sponsor: Theodoros Foukakis